Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Pharmacogenetic associations with cytochrome P450 in antiretroviral therapy: what does the future hold?

Expert opinion on drug metabolism & toxicology - 1 Jun 2018

Stillemans Gabriel, Belkhir Leila, Hesselink Dennis A, Haufroid Vincent, Elens Laure

Abstract excerpt

INTRODUCTION: Several antiretroviral drugs used to treat infection with the human immunodeficiency virus (HIV) are substrates of enzymes belonging to the cytochrome P450 (CYP) superfamily, which are polymorphically expressed. It may therefore be useful to take into account the genetic variation in these enzymes to predict the likelihood of anti-HIV treatment success, toxicity and the potential for drug-drug...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anti-HIV Agents
Share to Cytochrome P-450 Enzyme System

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Interactions

Share to Genetic Variation

Share to HIV Infections

Share to Pharmacogenetics

Source

Identifiers

PMID: 29775551
DOI: 10.1080/17425255.2018.1478964

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Pharmacogenetic associations with cytochrome P450 in antiretroviral therapy: what does the future hold?PMID 29775551Read ↗

Pharmacogenetic considerations for HIV treatment in different ethnicities: an update.Semantic proximity Read ↗

Pharmacogenomics of CYP3A: considerations for HIV treatment.Semantic proximity Read ↗

Pharmacogenetics of antiretroviral drugs for the treatment of HIV-infected patients: An updateSemantic proximity Read ↗

Pharmacogenetics of CYP2B6, CYP2A6 and UGT2B7 in HIV treatment in African populations: focus on efavirenz and nevirapine.Semantic proximity Read ↗

Approaches for understanding and predicting drug interactions in human immunodeficiency virus-infected patientsSemantic proximity Read ↗

Pharmacogenetics of anti-HIV drugs.Semantic proximity Read ↗

The dual role of pharmacogenetics in HIV treatment: mutations and polymorphisms regulating antiretroviral drug resistance and disposition.Semantic proximity Read ↗

Cytochrome P450 in Pharmacogenetics: An Update.Semantic proximity Read ↗

Pharmacogenetics of cytochrome P450 and its applications in drug therapy: the past, present and future.Semantic proximity Read ↗

Prevalence of Cytochrome P450 2B6 Single Nucleotide Polymorphism in an HIV-Positive Cohort in Jos, Nigeria: Implication for HIV Therapy.Semantic proximity Read ↗

Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects.Semantic proximity Read ↗

Pharmacogenetics of antiretroviral therapy: genetic variation of response and toxicity.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.